



19 January 2012  
EMA/CHMP/8919/2012  
Press Office

## Opinions on annual reassessments, 5-year renewals

Adopted at the CHMP meeting of 16-19 January 2012

**Table 1.** Opinions for annual re-assessment applications

Name of medicinal product (INN) MAH	Outcome	Comments
<b>Ventavis</b> (Iloprost), Bayer Pharma AG	Positive Opinion	Marketing Authorisation remains under exceptional circumstances

**Table 2.** Opinion for renewals of conditional Marketing Authorisation

Name of medicinal product (INN) MAH	Outcome	Comments
N/A		

**Table 3.** Opinion for 5-Year Renewal applications

Name of medicinal product (INN) MAH	Outcome	Comments
<b>Orencia</b> (Abatacept), Bristol- Myers Squibb Pharma EEIG	Positive Opinion	Unlimited validity
<b>Toviaz</b> (Fesoterodine), Pfizer Ltd	Positive Opinion	Unlimited validity

**Table 4.** Accelerated Assessment Procedures

Substance (Chemical/Biological)	Intended indication(s)	Accelerated Assessment Request	
		Accepted	Rejected
N/A			

